Coloplast A/S (COLO-B) Fair Value & Analysis
Healthcare · DK · Market cap 93.3B DKK
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 4 days ago
Fair value updated Jul 17, 2026, revised from kr 385.75 to kr 382.22 (−0.9%) since Jul 15, 2026. Share price +10.5% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 372.30 – kr 603.64 · fair‑value band kr 242.66 – kr 482.19 · the kr 418.40 price screens above the kr 382.22 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Coloplast A/S (COLO-B) currently trades at kr 418.40, while our model-based Fair Value estimate is kr 382.22, implying the stock looks roughly 8.7% fairly valued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Coloplast A/S generated revenue of 28.0B DKK at a net margin of 7.5%. Revenue grew 2.2% year over year. It earns a return on equity of 14.1%. Net debt stands at 21.7B DKK. Fundamentals as of Jul 17, 2026
Our scenario range runs from kr 242.66 (bear case) to kr 482.19 (bull case); at kr 418.40, the current price sits within that range. The share trades about 32% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside, at -9%, COLO-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Coloplast A/S reported revenue of kr 27.9B in FY2025 versus kr 19.4B in FY2021, a compound +9.4%/yr. Reported net income was kr 3.6B in FY2025, compounding −6.8%/yr from FY2021.
Is COLO-B fairly valued? → Check now
Recent news
- Jette Nygaard-Andersen Joins LivaNova Board as a New Director
- Coloplast’s Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men
- 3 European Stocks Possibly Trading At Discounts Of Up To 39.2%
- Uncovering 3 European Stocks That May Be Priced Below Intrinsic Value Estimates
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | C$20.93 | C$10.43 | -50% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $65.18 | $44.21 | -32% |
| ResMed Inc RMD | $196.04 | $185.14 | -6% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $12.68 | $5.49 | -57% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Coloplast A/S (COLO-B) undervalued?
What is the fair value of COLO-B?
What is the quality score of COLO-B?
What is the revenue of Coloplast A/S (COLO-B)?
What is the net profit margin of COLO-B?
Does Coloplast A/S pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Coloplast A/S analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.